Aethlon Medical Net Income 2006-2018 | AEMD

Aethlon Medical net income from 2006 to 2018. Net income can be defined as company's net profit or loss after all revenues, income items, and expenses have been accounted for.
Aethlon Medical Annual Net Income
(Millions of US $)
2018 $-6
2017 $-7
2016 $-5
2015 $-7
2014 $-13
2013 $-5
2012 $-8
2011 $-6
2010 $-5
2009 $-6
2008 $-4
2007 $-6
2006 $-3
2005 $-2
Aethlon Medical Quarterly Net Income
(Millions of US $)
Q3 2018 $-2
Q2 2018 $-1
Q1 2018 $-1
Q4 2018 $-1
Q3 2017 $-1
Q2 2017 $-1
Q1 2017 $-2
Q4 2017 $-2
Q3 2016 $-1
Q2 2016 $-2
Q1 2016 $-2
Q4 2016 $-1
Q3 2015 $-1
Q2 2015 $-1
Q1 2015 $-1
Q4 2015 $-1
Q3 2014 $-2
Q2 2014 $-1
Q1 2014 $-4
Q4 2014 $-7
Q3 2013 $-2
Q2 2013 $-3
Q1 2013 $-0
Q4 2013 $-3
Q3 2012 $0
Q2 2012 $-1
Q1 2012 $-1
Q4 2012 $-4
Q3 2011 $-1
Q2 2011 $-0
Q1 2011 $-3
Q4 2011 $2
Q3 2010 $-2
Q2 2010 $-3
Q1 2010 $-3
Q4 2010 $-1
Q3 2009 $-1
Q2 2009 $-1
Q1 2009 $-1
Q4 2009 $-1
Q3 2008 $-2
Q2 2008 $-2
Q1 2008 $-1
Q4 2008 $-1
Q3 2007 $-3
Q2 2007 $-0
Q1 2007 $-1
Q4 2007 $-4
Q3 2006 $-1
Q2 2006 $-1
Q1 2006 $-1
Q4 2006 $-1
Q3 2005 $-1
Q2 2005 $-1
Q1 2005 $-1
Q4 2005 $-1
Sector Industry Market Cap Revenue
Medical Medical - Health Maintenance Organizations $0.008B $0.000B
Aethlon Medical, Inc. is a development stage medical device company focused on expanding the applications of our Hemopurifier (R) platform technology, which is designed to rapidly reduce the presence of infectious viruses and other toxins from human blood. In this regard, its core focus is the development of therapeutic devices that treat acute viral conditions, chronic viral diseases and pathogens targeted as potential biological warfare agents. The Hemopurifier(R) combines the established scientific principles of affinity chromatography and hemodialysis as a means to mimic the immune system's response of clearing viruses and toxins from the blood before cell and organ infection can occur. The Hemopurifier(R) cannot cure viral conditions but can prevent virus and toxins from infecting unaffected tissues and cells. The company has completed pre-clinical blood testing of the Hemopurifier(R) to treat HIV and Hepatitis-C, and have completed human safety trials on Hepatitis-C infected patients in India.
Stock Name Country Market Cap PE Ratio
UnitedHealth Group (UNH) United States $229.394B 17.80
Anthem (ANTM) United States $68.175B 16.04
Humana (HUM) United States $33.464B 15.81
Centene (CNC) United States $23.154B 14.46
WellCare Health Plans (WCG) United States $13.818B 22.26
Molina Healthcare (MOH) United States $8.121B 10.91
Select Medical Holdings (SEM) United States $1.989B 14.54
Magellan Health (MGLN) United States $1.629B 34.05
Triple-S Management (GTS) United States $0.615B 39.16
Joint (JYNT) United States $0.255B 131.93